| scholarly article | Q13442814 |
| P50 | author | Vladimir J N Bykov | Q88401820 |
| Natalia Issaeva | Q95974506 | ||
| Galina Selivanova | Q50923870 | ||
| Klas Wiman | Q57419790 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | statistics | Q12483 |
| database | Q8513 | ||
| P304 | page(s) | 2011-2018 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Carcinogenesis | Q326022 |
| P1476 | title | Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database | |
| P478 | volume | 23 |
| Q35640128 | A new therapeutic basis for treating Li-Fraumeni Syndrome breast tumors expressing mutated TP53. |
| Q38851714 | APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma |
| Q52579544 | APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. |
| Q37577458 | APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase |
| Q33648548 | Alpha-santalol, a chemopreventive agent against skin cancer, causes G2/M cell cycle arrest in both p53-mutated human epidermoid carcinoma A431 cells and p53 wild-type human melanoma UACC-62 cells |
| Q35946185 | Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. |
| Q37162374 | Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice |
| Q35094229 | Chemotherapeutic approaches for targeting cell death pathways |
| Q39020380 | Computational Search for Possible Mechanisms of 4-Thiazolidinones Anticancer Activity: The Power of Visualization |
| Q24628577 | Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 |
| Q35101871 | Drug discovery and p53. |
| Q40502956 | Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. |
| Q79610624 | Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus |
| Q34058079 | Ensemble-based computational approach discriminates functional activity of p53 cancer and rescue mutants |
| Q36147271 | Function of hyperekplexia-causing α1R271Q/L glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway |
| Q35927115 | In vivo tumor growth of high-grade serous ovarian cancer cell lines |
| Q39863720 | Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L). |
| Q39961048 | Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival |
| Q92445781 | Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy |
| Q92736081 | Mutant p53 on the Path to Metastasis |
| Q41968106 | Mutant p53 targeting by the low molecular weight compound STIMA-1 |
| Q38746991 | Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? |
| Q40113704 | Mutated and non-mutated TP53 as targets in the treatment of leukaemia. |
| Q40203796 | Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. |
| Q26796485 | Next-generation sequencing: hype and hope for development of personalized radiation therapy? |
| Q35597613 | Novel cancer therapy by reactivation of the p53 apoptosis pathway. |
| Q36794233 | PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation |
| Q46883864 | PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion |
| Q40243688 | PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins |
| Q30486972 | PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein. |
| Q39659292 | PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73 |
| Q52649897 | Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. |
| Q40401654 | Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q39529355 | Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q30831001 | Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. |
| Q64231035 | Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket |
| Q35204556 | Small molecules that reactivate mutant p53. |
| Q36430162 | Strategies for therapeutic targeting of the p53 pathway in cancer. |
| Q35646576 | TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. |
| Q35591708 | TRAIL and apoptosis induction by TNF-family death receptors. |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q26766341 | Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy |
| Q34636996 | Targeting p53 by small molecules in hematological malignancies |
| Q37506032 | Targeting the LKB1 tumor suppressor |
| Q37260683 | Targeting the p53 pathway |
| Q35795073 | Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils |
| Q58761640 | The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells |
| Q36025625 | The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q91898958 | Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia |
| Q34324683 | Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions |
| Q37323049 | Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma. |
| Q39634867 | p53 Dysfunction by Xeroderma Pigmentosum Group C Defects Enhance Lung Adenocarcinoma Metastasis via Increased Mmp1 Expression |
| Q28478414 | p53 transactivation and the impact of mutations, cofactors and small molecules using a simplified yeast-based screening system |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q35103143 | p73 in Cancer. |
Search more.